|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.26 CHF | -0.32% |
|
+3.33% | +25.45% |
| 07-08 | DSM-Firmenich slips despite share buybacks and Jefferies' positive view | |
| 07-01 | What to know about sunscreens in heat waves | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 9.2B | 8.39B | 10.63B | 12.8B | 9.03B | |||||
Total Revenues | 9.2B | 8.39B | 10.63B | 12.8B | 9.03B | |||||
Cost of Goods Sold, Total | 6.04B | 5.7B | 8.02B | 8.55B | 5.5B | |||||
Gross Profit | 3.16B | 2.69B | 2.61B | 4.24B | 3.53B | |||||
Selling General & Admin Expenses, Total | 1.79B | 1.77B | 2.54B | 2.85B | 2.21B | |||||
R&D Expenses | 323M | 295M | 652M | 888M | 713M | |||||
Other Operating Expenses | 29M | -29M | -16M | 0 | -21M | |||||
Other Operating Expenses, Total | 2.14B | 2.04B | 3.17B | 3.74B | 2.9B | |||||
Operating Income | 1.02B | 652M | -560M | 509M | 629M | |||||
Interest Expense, Total | -92M | -104M | -138M | -162M | -154M | |||||
Interest And Investment Income | 3M | 22M | 95M | 70M | 60M | |||||
Net Interest Expenses | -89M | -82M | -43M | -92M | -94M | |||||
Income (Loss) On Equity Invest. | 16M | 12M | -6M | -5M | -102M | |||||
Currency Exchange Gains (Loss) | -7M | -20M | -86M | -41M | -51M | |||||
Other Non Operating Income (Expenses) | -15M | -1M | -26M | 1M | 4M | |||||
EBT, Excl. Unusual Items | 928M | 561M | -721M | 372M | 386M | |||||
Merger & Related Restructuring Charges | -25M | -3M | -59M | -39M | -2M | |||||
Gain (Loss) On Sale Of Investments | 326M | -7M | -1M | 5M | -6M | |||||
Gain (Loss) On Sale Of Assets | 13M | 31M | 17M | 47M | 43M | |||||
Insurance Settlements | 11M | 12M | 53M | 21M | 39M | |||||
Legal Settlements | 2M | - | - | - | - | |||||
Other Unusual Items | 2M | 5M | 57M | 21M | - | |||||
EBT, Incl. Unusual Items | 1.26B | 599M | -654M | 427M | 460M | |||||
Income Tax Expense | 168M | 124M | -18M | 147M | 118M | |||||
Earnings From Continuing Operations | 1.09B | 475M | -636M | 280M | 342M | |||||
Earnings Of Discontinued Operations | 591M | 1.24B | 2.79B | - | -1.38B | |||||
Net Income to Company | 1.68B | 1.72B | 2.15B | 280M | -1.04B | |||||
Minority Interest | -4M | -15M | -16M | -30M | -42M | |||||
Net Income - (IS) | 1.68B | 1.7B | 2.14B | 250M | -1.08B | |||||
Preferred Dividend and Other Adjustments | 6M | 6M | 6M | - | 26M | |||||
Net Income to Common Incl Extra Items | 1.67B | 1.69B | 2.13B | 250M | -1.11B | |||||
Net Income to Common Excl. Extra Items | 1.08B | 454M | -658M | 250M | 274M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 9.67 | 9.8 | 9.14 | 0.94 | -4.27 | |||||
Basic EPS - Continuing Operations | 6.25 | 2.63 | -2.82 | 0.94 | 1.06 | |||||
Basic Weighted Average Shares Outstanding | 173M | 173M | 233M | 265M | 259M | |||||
Net EPS - Diluted | 9.63 | 9.77 | 9.14 | 0.94 | -4.27 | |||||
Diluted EPS - Continuing Operations | 6.22 | 2.61 | -2.82 | 0.94 | 1.05 | |||||
Diluted Weighted Average Shares Outstanding | 173M | 173M | 233M | 265M | 259M | |||||
Normalized Basic EPS | 3.34 | 1.94 | -2 | 0.77 | 0.77 | |||||
Normalized Diluted EPS | 3.32 | 1.94 | -2 | 0.77 | 0.77 | |||||
Dividend Per Share | 2.5 | 2.53 | 2.5 | 2.5 | 2.5 | |||||
Payout Ratio | 15.87 | 20.29 | 7.35 | 264 | -60.96 | |||||
American Depositary Receipts Ratio (ADR) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.62B | 1.23B | 352M | 1.6B | 1.44B | |||||
EBITA | 1.24B | 892M | -83M | 1.12B | 1.17B | |||||
EBIT | 1.02B | 652M | -560M | 509M | 629M | |||||
Effective Tax Rate - (Ratio) | 13.37 | 20.7 | 2.75 | 34.43 | 25.65 | |||||
Total Current Taxes | 122M | 107M | 188M | 324M | 223M | |||||
Total Deferred Taxes | 46M | 17M | -206M | -177M | -105M | |||||
Normalized Net Income | 576M | 336M | -467M | 202M | 199M | |||||
Interest Capitalized | 4M | 3M | 4M | 6M | 9M | |||||
Interest on Long-Term Debt | 5M | 6M | 8M | 15M | 17M | |||||
Non-Cash Pension Expense | -7M | 1M | 7M | 9M | 11M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 1.27B | 1.24B | 1.51B | 1.8B | 1.28B | |||||
General and Administrative Expenses | 517M | 534M | 1.02B | 1.04B | 925M | |||||
Research And Development Expense From Footnotes | 334M | 295M | 652M | 888M | 713M | |||||
Stock-Based Comp., Other (Total) | 22M | 35M | 29M | 35M | 35M | |||||
Total Stock-Based Compensation | 22M | 35M | 29M | 35M | 35M |
- Stock Market
- Stocks
- DSFIR Stock
- Financials DSM-Firmenich
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















